Indication
MOG-AD
1 clinical trial
1 product
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)Status: Recruiting, Estimated PCD: 2026-08-10
Product
Rozanolixizumab